Archived article
Please note that tax, investment, pension and ISA rules can change and the information and any views contained in this article may now be inaccurate.
DXS International PLC on Thursday said it has signed a licence & services agreement with AI company Deontics Ltd.
DXS is a Leicestershire, England-based healthcare information and clinical decision support systems provider. Deontics is a clinical AI company, which spun out from Oxford University, Cancer Research UK and University College London. It currently provides for around 2,500 practices serving 16 million patients.
The company said that by integrating the Deontics engine into the DSX platform, the partnership aims to save clinician time, help with decision fatigue and integrate pathways in clinician's workflows. These are some of the ‘most critical objectives’ in healthcare, DSX added.
‘Deontics has solved these challenges; it is unique in its offering and the only solution on the market that blends clinical process (workflow) and complex reasoning and knowledge representation and is capable of running the pathway both prospectively on individual patient data and retrospectively on batch data,’ the company explained.
Further, the integration will allow DXS to offer additional features and functions to its customers, including advanced third generation clinical decision support and advanced analytics.
‘By DXS integrating the Deontics Advanced AI engine, DXS can offer improvements to the adoption of pathways, making consultations more efficient, improving data quality, reducing decision fatigue for busy GPs, and ultimately improving patient outcomes,’ the company added.
Shares in DXS were untraded at 10.00 pence each in London on Thursday afternoon.
Copyright 2022 Alliance News Limited. All Rights Reserved.